Navigation Links
IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
Date:12/10/2012

's actual results and financial position to differ materially from those included within the forward-looking statements. Forward-looking statements involve risks and uncertainties, including those relating to the Company's ability to grow its business. Actual results may differ materially from the results predicted and reported results should not be considered as an indication of future performance. The potential risks and uncertainties include, among others, the Company's limited operating history, the limited financial resources, domestic or global economic conditions, activities of competitors and the presence of new or additional competition, and changes in Federal or State laws. More information about the potential factors that could affect the Company's business and financial results is included in the Company's filings, available via the United States Securities and Exchange Commission.

Contact:
IntelliCell BioSciences, Inc.
Robert J. Sexauer
Email:  rsexauer@intellicellbiosciences.com 
(646) 576-8706  


'/>"/>
SOURCE IntelliCell BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. IntelliCell BioSciences Signs Technology Licensing Agreement with Stem Cells 21 Thailand
2. IntelliCell BioSciences Expands Management Team
3. IntelliCell BioSciences Announces Collaborative Agreement with the University of Florida on Stem Cell and Tissue Repair Research
4. IntelliCell BioSciences Announces Myron Z. Holubiak Joins the IntelliCell BioSciences Board of Directors
5. IntelliCell BioSciences Announces It Will Present and Run Workshop at the 10th Annual Commercialization of Regenerative Medicine in London
6. IntelliCell BioSciences Announces Michael Hershman Joins the IntelliCell BioSciences Board of Directors
7. IntelliCell BioSciences Announces Research Agreement with the New Jersey Center for Biomaterials at Rutgers-The State University of New Jersey
8. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
9. The Law Firm of Levi & Korsinsky, LLP Launches an Investigation Into Possible Securities Laws Violations by Pacific Biosciences of California, Inc.
10. Coronado Biosciences to Present at the Oppenheimer 22nd Annual Healthcare Conference
11. Coronado Biosciences Announces Phase 1 Results of CNDO-109 in AML to be Presented at the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013 A recent study from researchers ... to find that those who took probiotics were able to ... the study showed that in extreme heat conditions, probiotics were ... adult acne treatment explains what this new discovery ... help their skin condition. , While researchers tote the ...
(Date:5/21/2013)... , May 21, 2013  The Lindsley F. Kimball Research ... it is a Grand Challenges Explorations winner, an ... .  Dr. Sara Lustigman , Head of ... health and development research project, titled Innovative 3-D ... worms are needed to screen drugs to help eliminate onchocerciasis ...
(Date:5/21/2013)... , May 21, 2013 ... Dialysis and Transplant Association) is the biggest congress in ... replacement therapy. Nearly 10,000 participants are in ... the latest research findings. New pioneering studies have been ... "SOLUBLE FERRIC PYROPHOSPHATE (SFP) ADMINISTERED VIA HEMODIALYSATE REDUCES ESA ...
(Date:5/21/2013)... 2013 As the R&D sector ... within the industry to deliver better products, faster. ... pharma companies often means turning big ideas into ... in collaboration with Sensidose AB and Recipharm, is ... products to market sooner. The partnership resulted in ...
Breaking Biology Technology:Adult Acne Treatment, Probiotic Action Shares Insight on New Findings Between Probiotics and Heat Tolerance, and What It Means for Acne Sufferers 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 2New York Blood Center's Research Institute Receives Grand Challenges Explorations Grant For Groundbreaking Research in Global Health and Development 3ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 2ERA-EDTA CONGRESS 2013: Late Breaking Clinical Trials 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2
... Member of Select Group of Companies, Permitted to Bid as Prime Contractor ... ... Maximum of $4 Billion in Contract Value to be Awarded under ESD, ... subsidiary today announced that ViPS has,been selected as an information technology partner by ...
... a,business unit of PAREXEL International (Nasdaq: PRXL ... the bio/pharmaceutical and medical device,industries, announced today that ... in Europe to help its global client base,address ... such as,manufacturing regulations, quality, and safety. This ...
... Sosei Group Corporation,("Sosei"; TSE Mothers Index: 4565), the ... of an approved, centrally acting,non-opioid, analgesic, has completed ... treatment of fibromyalgia syndrome (FMS). The trial, ... study, investigated the efficacy,safety and tolerability of AD ...
Cached Biology Technology:ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS 2ViPS Awarded Enterprise Systems Development (ESD) Contract By CMS 3Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 2Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 3Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 4Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 5Parexel Consulting Strengthens Good Manufacturing Practice Capabilities in Europe 6Sosei Announces Completion of Phase II Trial of AD 337 in Fibromyalgia Syndrome 2
(Date:5/21/2013)... and health stores, phosphatidylserine is a natural food ... to improve cognition and slow memory loss, it,s ... impairment. Now a team headed by Prof. Gil ... University,s Department of Human Molecular Genetics ... functioning of genes involved in degenerative brain disorders, ...
(Date:5/21/2013)... largest gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... research, resource assessment, market and policy developments, manufacturing and ... world and benefiting from its 2013 edition from a ... than 60 countries, more than 240 plenary and oral ...
(Date:5/20/2013)... 20, 2013) University of Minnesota Medical School researchers ... partnership with the University,s Brain Tumor Program, have developed ... tumors (MPNST) that allow them to discover new genes ... The research was published this week in the journal ... transposon method, researchers in the lab of David Largaespada, ...
Breaking Biology News(10 mins):Common food supplement fights degenerative brain disorders 221st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4U of M researchers develop model for better testing, targeting of MPNST 2
... the Max Delbrck Center for Molecular Medicine (MDC) Berlin-Buch, ... By measuring electrical impulses in the sensory neurons of ... Lechner and Professor Gary Lewin were able to directly ... At the same time they were able to show ...
... latest special issue of S cience in China Series C: ... H5N1-related research field. Early 2009, eight human infection cases ... death cases, were reported in China. This again made the ... avian-origin influenza virus. Again H5N1 is in the spotlight of ...
... Although a test for gene mutations known to significantly ... has been available for more than a decade, a ... of these cancers are even discussing genetic testing with ... a report in the Journal of General Internal ...
Cached Biology News:Investigating the development of mechanosensitivity 2The challenges of avian influenza virus: Mechanism, epidemiology and control 2The challenges of avian influenza virus: Mechanism, epidemiology and control 3The challenges of avian influenza virus: Mechanism, epidemiology and control 4Genetic testing for breast or ovarian cancer risk may be greatly underutilized 2